Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. ("GuideAI" or the "Company") is pleased to announce that it has received 510(k) clearance from the U.S. Food and Drug Administration...
-
Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path Architecture Supports Future Expansion into Denervation,...
-
MONTREAL, June 22, 2026 (GLOBE NEWSWIRE) -- With thousands of Quebecers expected to take part in Saint-Jean-Baptiste Day, La fête nationale du Québec, MADD Canada encourages everyone to make road...
-
MONTRÉAL, 22 juin 2026 (GLOBE NEWSWIRE) -- Alors que des milliers de Québécois et de Québécoises se préparent à célébrer la Saint-Jean-Baptiste, la fête nationale du Québec, MADD Canada lance...
-
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced...
-
TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative...
-
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution...
-
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in...
-
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was...
-
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly...